Couto PS, Bersenev A, Verter F. The first decade of advanced cell therapy clinical trials using perinatal cells (2005-2015).
Regen Med 2017;
12:953-968. [PMID:
29139329 DOI:
10.2217/rme-2017-0066]
[Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
AIM
The first review of advanced cell therapy trials with perinatal cells.
MATERIALS & METHODS
We compiled 281 clinical trials of advanced cell therapy with perinatal cells that were registered in 2005-2015.
RESULTS
The most common cell source in these trials is cord blood, but the cell type that provides the mechanism of action in the majority of trials is mesenchymal stem/stromal cells. We analyze trends among the 15 parameters we compiled for these trials.
CONCLUSION
Advanced cell therapy with perinatal cells is a new field that covers a wide range of diagnoses but where most of the trials are early Phase. Researchers in different countries tend to work with a preferred cell source and cell type.
Collapse